Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887520 · ClinicalTrials.gov registry record · NA
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
A NA study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 49,001
- Enrollment target
NCT03887520: Completed NA study, sponsored by Novartis Pharmaceuticals.
NCT03887520 is a NA study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 49,001 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (3393% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03887520, a NA study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 49,001 participants
- Enrollment target
Study Summary
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
Primary Outcome
Prevalence of normal and elevated Lp(a) levels in patients with established CVD
Interventions
- DIAGNOSTIC_TEST Blood draw for Lp(a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,001 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2021-07-30 |
| Phase | NA |
What the finished NCT03887520 record still lists
NCT03887520 is an interventional study that assigns participants to a tested intervention. Its 49,001 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (3393% higher).
The record links to 0 conditions, and to 1 intervention - of which Blood draw for Lp(a) is the first listed.
NCT03887520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03887520 about?
NCT03887520 is a clinical study titled "Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)". The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
What is the current status of trial NCT03887520?
This trial is currently completed. It is a NA study. The enrollment target is 49,001 participants. The study started on 2018-11-27. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT03887520?
The interventions under investigation include: Blood draw for Lp(a) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03887520?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03887520's enrollment target sits among peer trials
49,001 7th of 2000 higher than 1,994 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI